Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder
Gary Zammit, Yves Dauvilliers, Scott Pain, et al.
Neurology (2020) Vol. 94, Iss. 21
Closed Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 2, pp. 125-139
Closed Access | Times Cited: 145
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Dieter Kunz, Yves Dauvilliers, Heike Beneš, et al.
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 93-106
Open Access | Times Cited: 52
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care
Jason Ellis, Luigi Ferini‐Strambi, Diego García‐Borreguero, et al.
Healthcare (2023) Vol. 11, Iss. 5, pp. 716-716
Open Access | Times Cited: 17
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
Mengzhen Zhou, Shi Tang
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 13
Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group
Laura Palagini, Raffaele Manni, Claudio Liguori, et al.
Journal of Neurology (2023) Vol. 271, Iss. 4, pp. 1668-1679
Closed Access | Times Cited: 13
The interaction between orexin, sleep deprivation and Alzheimer’s disease: Unveiling an Emerging Connection
Masoumeh Kourosh‐Arami, Mahdi Ramezani, Alireza Komaki‬
The Journal of Physiological Sciences (2025) Vol. 75, Iss. 1, pp. 100004-100004
Open Access
Discovery of IDOR-1117-1680, a dual orexin receptor antagonist with fast onset and short duration of action for the treatment of insomnia
Jean‐Philippe Surivet, Elise M. Jacob, Melanie Keßler, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 122, pp. 118132-118132
Closed Access
Dual orexin receptor antagonists as promising therapeutics for Alzheimer’s disease
Sydney M. Ragsdale, John M. Radovich, Isabel I. Coiduras, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Open Access
A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia
Katharina Lederer, Heike Beneš, Alan Fine, et al.
Journal of Sleep Research (2025)
Open Access
Comparison of efficacy and safety of dual orexin receptor antagonists lemborexant and daridorexant for the treatment of insomnia: a systematic review and meta-analysis
Ming Tang, Ziyi Shen, Peilu Yu, et al.
Psychopharmacology (2025)
Closed Access
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea
Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
SLEEP (2020) Vol. 44, Iss. 6
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top